Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of Dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (6 months to <6 years)
2016-000955-28Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary endpoints Part A. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-000955-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000955-28.